Atlassian Co. (NASDAQ:TEAM – Get Free Report) CEO Michael Cannon-Brookes sold 7,948 shares of Atlassian stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $161.30, for a total transaction of $1,282,012.40. Following the sale, the chief executive officer now owns 7,948 shares of the company’s stock, valued at $1,282,012.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Michael Cannon-Brookes also recently made the following trade(s):
- On Wednesday, September 25th, Michael Cannon-Brookes sold 7,948 shares of Atlassian stock. The stock was sold at an average price of $161.98, for a total transaction of $1,287,417.04.
- On Monday, September 23rd, Michael Cannon-Brookes sold 7,948 shares of Atlassian stock. The stock was sold at an average price of $162.27, for a total transaction of $1,289,721.96.
- On Thursday, September 19th, Michael Cannon-Brookes sold 7,948 shares of Atlassian stock. The shares were sold at an average price of $163.56, for a total value of $1,299,974.88.
- On Monday, September 16th, Michael Cannon-Brookes sold 7,948 shares of Atlassian stock. The stock was sold at an average price of $165.03, for a total value of $1,311,658.44.
- On Thursday, September 5th, Michael Cannon-Brookes sold 7,948 shares of Atlassian stock. The stock was sold at an average price of $160.97, for a total value of $1,279,389.56.
- On Friday, August 30th, Michael Cannon-Brookes sold 7,948 shares of Atlassian stock. The shares were sold at an average price of $166.36, for a total value of $1,322,229.28.
- On Wednesday, August 21st, Michael Cannon-Brookes sold 7,948 shares of Atlassian stock. The stock was sold at an average price of $156.92, for a total transaction of $1,247,200.16.
- On Friday, August 16th, Michael Cannon-Brookes sold 7,948 shares of Atlassian stock. The shares were sold at an average price of $151.62, for a total transaction of $1,205,075.76.
- On Friday, August 9th, Michael Cannon-Brookes sold 7,948 shares of Atlassian stock. The shares were sold at an average price of $141.23, for a total transaction of $1,122,496.04.
- On Friday, August 2nd, Michael Cannon-Brookes sold 7,948 shares of Atlassian stock. The stock was sold at an average price of $144.73, for a total value of $1,150,314.04.
Atlassian Price Performance
Shares of NASDAQ:TEAM opened at $161.42 on Wednesday. Atlassian Co. has a one year low of $135.29 and a one year high of $258.69. The stock has a market cap of $41.97 billion, a PE ratio of -252.08 and a beta of 0.73. The business’s fifty day moving average price is $159.98 and its two-hundred day moving average price is $173.22. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.18 and a current ratio of 1.18.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on TEAM shares. Mizuho decreased their target price on Atlassian from $225.00 to $220.00 and set an “outperform” rating for the company in a research report on Tuesday, July 16th. Wells Fargo & Company decreased their price objective on Atlassian from $285.00 to $250.00 and set an “overweight” rating for the company in a report on Friday, June 21st. Capital One Financial raised shares of Atlassian from an “equal weight” rating to an “overweight” rating and set a $211.00 target price on the stock in a report on Thursday, July 11th. Truist Financial decreased their price target on shares of Atlassian from $200.00 to $160.00 and set a “hold” rating for the company in a research note on Friday, August 2nd. Finally, Raymond James upgraded shares of Atlassian from a “market perform” rating to an “outperform” rating and set a $200.00 price objective on the stock in a research note on Tuesday. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $216.65.
View Our Latest Analysis on Atlassian
Hedge Funds Weigh In On Atlassian
A number of institutional investors have recently modified their holdings of TEAM. Dragoneer Investment Group LLC acquired a new stake in Atlassian during the second quarter worth approximately $469,803,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Atlassian by 8.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,141,645 shares of the technology company’s stock worth $2,173,847,000 after purchasing an additional 904,138 shares during the period. Manning & Napier Advisors LLC purchased a new position in shares of Atlassian during the 2nd quarter worth $91,072,000. Vanguard Group Inc. boosted its holdings in shares of Atlassian by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 15,355,652 shares of the technology company’s stock worth $3,652,495,000 after purchasing an additional 504,181 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in shares of Atlassian in the first quarter valued at $55,307,000. Institutional investors and hedge funds own 93.03% of the company’s stock.
About Atlassian
Atlassian Corporation, through its subsidiaries, designs, develops, licenses, and maintains various software products worldwide. Its product portfolio includes Jira Software and Jira Work Management, a project management system that connects technical and business teams so they can better plan, organize, track and manage their work and projects; Confluence, a connected workspace that organizes knowledge across all teams to move work forward; and Trello, a collaboration and organization product that captures and adds structure to fluid and fast-forming work for teams.
See Also
- Five stocks we like better than Atlassian
- Differences Between Momentum Investing and Long Term Investing
- Why Lennar Stock Could Be the Best Play in the Housing Market
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- P/E Ratio Calculation: How to Assess Stocks
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Atlassian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atlassian and related companies with MarketBeat.com's FREE daily email newsletter.